This Enspryng market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the high prevalence of multiple sclerosis (MS), the adoption of immunosuppressive drugs, increased prevalence correlated with MG activity, and a rise in research and development activities.
Growth in the forecast period is expected to result from increased investment in healthcare infrastructure, rising healthcare expenditure, a growing geriatric population, expanding research and development efforts, and a rising prevalence of neuromyelitis optica. Key trends anticipated during the forecast period include the introduction of new products and therapies, technological advancements, innovative drugs, antibody recycling technologies, and strategic partnerships and collaborations.
The increasing prevalence of multiple sclerosis is anticipated to drive the growth of the enspryng market in the future. Multiple Sclerosis (MS) is a chronic disorder of the central nervous system (CNS), affecting the brain and spinal cord. The rising prevalence of MS is largely due to advancements in diagnostic imaging techniques and improved reporting, leading to earlier and more accurate detection. Enspryng (satralizumab) is employed in treating relapsing forms of MS by inhibiting the interleukin-6 receptor to reduce inflammation and prevent nerve damage. It is administered through monthly subcutaneous injections. For example, in May 2024, according to the Multiple Sclerosis Society, a UK-based charity for individuals affected by MS, over 7,100 people are diagnosed with the condition annually, with 71% of them being women, making women 2.5 times more likely than men to develop MS. Consequently, the rising prevalence of multiple sclerosis is fueling the growth of the enspryng market.
Increasing healthcare investment is also expected to propel the growth of the enspryng market moving forward. Healthcare investment involves allocating financial resources, including capital and operational funding, to healthcare-related services, technologies, and initiatives. The rapid adoption of telemedicine and AI-powered diagnostics is driving substantial healthcare investments, promising enhanced patient outcomes and greater operational efficiencies. These investments have supported the development, regulatory approval, manufacturing, and global distribution of Enspryng, ensuring its availability for patients with neuromyelitis optica spectrum disorder. For instance, in November 2024, the Health Foundation, a UK-based independent charity, reported that planned healthcare spending would rise from approximately $221.1bn (£177.9bn) in cash terms to $237.4bn (£190.1bn) in 2024/25 and $250.1bn (£200.5bn) in 2025/26. After accounting for changes in pensions policy, this represents an average annual real-term growth of 3.3% since 2023/24. Therefore, increasing investment in healthcare is driving the expansion of the enspryng market.
A significant trend in the enspryng (Ofatumumab) market is securing regulatory product approvals to broaden its clinical indications. Regulatory product approvals involve a government or regulatory body formally evaluating and authorizing a product for sale and use within a specific market. For instance, in June 2021, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, received approval from the European Commission for Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD), targeting patients with anti-aquaporin-4 (AQP4-IgG) antibodies. This innovative therapy can be self-administered every four weeks after appropriate training, offering greater convenience for patients compared to traditional intravenous treatments. Clinical trials demonstrated remarkable efficacy, with a 74% reduction in relapse risk and a favorable safety profile.
The key company in the enspryng market is F. Hoffmann-La Roche AG.
North America was the largest region in the enspryng market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enspryng report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enspryng market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Enspryng (satralizumab) is a monoclonal antibody designed to treat neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 antibodies. It works by inhibiting the interleukin-6 receptor to reduce inflammation. Administered subcutaneously every four weeks after an initial loading phase, common side effects include headache and an increased risk of infections.
The primary indications for enspryng include neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG). NMOSD is a rare autoimmune disorder that predominantly impacts the central nervous system, especially the optic nerves and spinal cord. Enspryng is suitable for various age groups and seropositivity statuses, with distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies.
The enspryng market research report is one of a series of new reports that provides enspryng market statistics, including enspryng industry global market size, regional shares, competitors with an enspryng market share, detailed enspryng market segments, market trends and opportunities, and any further data you may need to thrive in the enspryng industry. This inspiring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The enspryng market consists of sales of products including satralizumab and prefilled syringes and monotherapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the high prevalence of multiple sclerosis (MS), the adoption of immunosuppressive drugs, increased prevalence correlated with MG activity, and a rise in research and development activities.
Growth in the forecast period is expected to result from increased investment in healthcare infrastructure, rising healthcare expenditure, a growing geriatric population, expanding research and development efforts, and a rising prevalence of neuromyelitis optica. Key trends anticipated during the forecast period include the introduction of new products and therapies, technological advancements, innovative drugs, antibody recycling technologies, and strategic partnerships and collaborations.
The increasing prevalence of multiple sclerosis is anticipated to drive the growth of the enspryng market in the future. Multiple Sclerosis (MS) is a chronic disorder of the central nervous system (CNS), affecting the brain and spinal cord. The rising prevalence of MS is largely due to advancements in diagnostic imaging techniques and improved reporting, leading to earlier and more accurate detection. Enspryng (satralizumab) is employed in treating relapsing forms of MS by inhibiting the interleukin-6 receptor to reduce inflammation and prevent nerve damage. It is administered through monthly subcutaneous injections. For example, in May 2024, according to the Multiple Sclerosis Society, a UK-based charity for individuals affected by MS, over 7,100 people are diagnosed with the condition annually, with 71% of them being women, making women 2.5 times more likely than men to develop MS. Consequently, the rising prevalence of multiple sclerosis is fueling the growth of the enspryng market.
Increasing healthcare investment is also expected to propel the growth of the enspryng market moving forward. Healthcare investment involves allocating financial resources, including capital and operational funding, to healthcare-related services, technologies, and initiatives. The rapid adoption of telemedicine and AI-powered diagnostics is driving substantial healthcare investments, promising enhanced patient outcomes and greater operational efficiencies. These investments have supported the development, regulatory approval, manufacturing, and global distribution of Enspryng, ensuring its availability for patients with neuromyelitis optica spectrum disorder. For instance, in November 2024, the Health Foundation, a UK-based independent charity, reported that planned healthcare spending would rise from approximately $221.1bn (£177.9bn) in cash terms to $237.4bn (£190.1bn) in 2024/25 and $250.1bn (£200.5bn) in 2025/26. After accounting for changes in pensions policy, this represents an average annual real-term growth of 3.3% since 2023/24. Therefore, increasing investment in healthcare is driving the expansion of the enspryng market.
A significant trend in the enspryng (Ofatumumab) market is securing regulatory product approvals to broaden its clinical indications. Regulatory product approvals involve a government or regulatory body formally evaluating and authorizing a product for sale and use within a specific market. For instance, in June 2021, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, received approval from the European Commission for Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD), targeting patients with anti-aquaporin-4 (AQP4-IgG) antibodies. This innovative therapy can be self-administered every four weeks after appropriate training, offering greater convenience for patients compared to traditional intravenous treatments. Clinical trials demonstrated remarkable efficacy, with a 74% reduction in relapse risk and a favorable safety profile.
The key company in the enspryng market is F. Hoffmann-La Roche AG.
North America was the largest region in the enspryng market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enspryng report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enspryng market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Enspryng (satralizumab) is a monoclonal antibody designed to treat neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 antibodies. It works by inhibiting the interleukin-6 receptor to reduce inflammation. Administered subcutaneously every four weeks after an initial loading phase, common side effects include headache and an increased risk of infections.
The primary indications for enspryng include neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG). NMOSD is a rare autoimmune disorder that predominantly impacts the central nervous system, especially the optic nerves and spinal cord. Enspryng is suitable for various age groups and seropositivity statuses, with distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies.
The enspryng market research report is one of a series of new reports that provides enspryng market statistics, including enspryng industry global market size, regional shares, competitors with an enspryng market share, detailed enspryng market segments, market trends and opportunities, and any further data you may need to thrive in the enspryng industry. This inspiring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The enspryng market consists of sales of products including satralizumab and prefilled syringes and monotherapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Enspryng Market Characteristics4. Enspryng Market Trends and Strategies5. Enspryng Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Enspryng Pricing Analysis & Forecasts30. Global Enspryng Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Enspryng Market32. Recent Developments in the Enspryng Market
3. Enspryng Market Biologic Drug Characteristics
6. Global Enspryng Growth Analysis and Strategic Analysis Framework
8. Enspryng Market Segmentation
9. Global Enspryng Epidemiology of Clinical Indications
10. Enspryng Market Regional and Country Analysis
11. Asia-Pacific Enspryng Market
12. China Enspryng Market
13. India Enspryng Market
14. Japan Enspryng Market
15. Australia Enspryng Market
16. South Korea Enspryng Market
17. Western Europe Enspryng Market
18. UK Enspryng Market
19. Germany Enspryng Market
20. France Enspryng Market
21. Eastern Europe Enspryng Market
22. North America Enspryng Market
23. USA Enspryng Market
24. Canada Enspryng Market
25. South America Enspryng Market
26. Middle East Enspryng Market
27. Africa Enspryng Market
28. Enspryng Market Competitive Landscape and Company Profiles
29. Global Enspryng Market Pipeline Analysis
33. Enspryng Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Enspryng Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on enspryng market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for enspryng? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The enspryng market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Neuromyelitis Optica Spectrum Disorder (NMOSD); Generalized Myasthenia Gravis (gMG)2) by Patient Demographics: Age Groups; Seropositivity
3) by Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Key Companies Mentioned: F. Hoffmann-La Roche AG
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche AG
